Turnstone Biologics CorpNASDAQ:TSBXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.4695
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.4580/ 5
- Ask / Lots0.5000/ 2
- Open / Previous Close--- / 0.4695
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TSBX |
|---|---|---|
| 09:32 ET | 163 | 0.4611 |
| 09:48 ET | 2000 | 0.46111 |
| 09:50 ET | 3500 | 0.4605 |
| 09:51 ET | 2000 | 0.4607 |
| 10:26 ET | 622 | 0.460701 |
| 10:29 ET | 500 | 0.4716 |
| 10:47 ET | 200 | 0.482 |
| 11:00 ET | 500 | 0.47035 |
| 11:05 ET | 10621 | 0.46 |
| 11:09 ET | 10710 | 0.4455 |
| 11:12 ET | 9609 | 0.4549 |
| 11:18 ET | 10150 | 0.45105 |
| 11:20 ET | 11100 | 0.4599 |
| 11:21 ET | 18369 | 0.478 |
| 11:25 ET | 182 | 0.4825 |
| 11:30 ET | 19260 | 0.4599 |
| 11:41 ET | 1000 | 0.460477 |
| 11:54 ET | 200 | 0.482 |
| 01:24 ET | 250 | 0.47 |
| 01:40 ET | 400 | 0.48 |
| 01:44 ET | 100 | 0.476 |
| 01:45 ET | 340 | 0.47 |
| 01:47 ET | 107 | 0.46 |
| 01:49 ET | 100 | 0.476 |
| 01:51 ET | 210 | 0.48 |
| 01:56 ET | 100 | 0.4764 |
| 01:58 ET | 400 | 0.48 |
| 02:02 ET | 100 | 0.48 |
| 02:03 ET | 330 | 0.48 |
| 02:05 ET | 200 | 0.48 |
| 02:09 ET | 400 | 0.47 |
| 02:12 ET | 200 | 0.48 |
| 02:16 ET | 400 | 0.48 |
| 02:18 ET | 100 | 0.476 |
| 02:21 ET | 600 | 0.47 |
| 02:23 ET | 200 | 0.48 |
| 02:27 ET | 300 | 0.48 |
| 02:30 ET | 200 | 0.48 |
| 02:32 ET | 400 | 0.47 |
| 02:38 ET | 300 | 0.47 |
| 02:39 ET | 1000 | 0.47 |
| 02:43 ET | 500 | 0.479 |
| 02:48 ET | 733 | 0.4602 |
| 02:50 ET | 400 | 0.479 |
| 02:52 ET | 366 | 0.4602 |
| 02:54 ET | 500 | 0.479 |
| 02:56 ET | 400 | 0.479 |
| 02:59 ET | 300 | 0.479 |
| 03:01 ET | 400 | 0.48 |
| 03:06 ET | 200 | 0.4701 |
| 03:08 ET | 10400 | 0.4701 |
| 03:12 ET | 3400 | 0.48 |
| 03:14 ET | 400 | 0.4701 |
| 03:17 ET | 1700 | 0.4701 |
| 03:19 ET | 400 | 0.4701 |
| 03:21 ET | 5000 | 0.4602 |
| 03:26 ET | 700 | 0.479 |
| 03:28 ET | 400 | 0.479 |
| 03:33 ET | 400 | 0.479 |
| 03:39 ET | 400 | 0.479 |
| 03:42 ET | 100 | 0.46 |
| 03:46 ET | 400 | 0.47 |
| 03:51 ET | 2200 | 0.4699 |
| 03:53 ET | 200 | 0.4695 |
| 03:55 ET | 100 | 0.4695 |
| 03:57 ET | 100 | 0.4695 |
| 04:00 ET | 200 | 0.4695 |
Nov 12, 2024
Press Release: Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights, from 4:05PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:05PM ET on Tuesday Nov 12, 2024 by Dow JonesTurnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights, from 4:05PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:05PM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 5, 2024
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting, from 9:01AM ET on Tuesday Nov 05, 2024 by Dow Jones
9:01AM ET on Tuesday Nov 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Turnstone Biologics Corp | 10.9M | -0.1x | --- |
Viaderma Inc | 10.7M | 0.0x | --- |
Cara Therapeutics Inc | 17.0M | -0.2x | --- |
HOOKIPA Pharma Inc | 27.7M | -0.6x | --- |
SQZ Biotechnologies Co | 781.5K | 0.0x | --- |
Gritstone bio Inc | 3.2M | 0.0x | --- |
Company Information
Turnstone Biologics Corp. is a clinical-stage biotechnology company. The Company is focused on developing new medicines to treat and cure patients with solid tumors. It is developing tumor infiltrating lymphocytes (TIL) therapies for the potential treatment of multiple solid tumors. It is also actively advancing its preclinical pipeline programs including TIDAL-02, its next Selected TIL program, and its TIDAL-01 and viral immunotherapy combination program. It is advancing TIDAL-01, its lead Selected TIL product candidate, for the treatment of multiple solid tumor indications. TIDAL-01 utilizes an unbiased identification and functional screening process to isolate and selectively expand the greatest breadth of tumor-reactive TILs from the patient’s tumor. Its next Selected TIL program, TIDAL-02, is being designed to encompass a next generation streamlined manufacturing process for tumor-reactive T cells and additional modifications to enhance TIL quality and function.
Contact Information
- Headquarters
- 9310 Athena Circle, Suite 300LA JOLLA, CA, United States 92037
- Phone
- 347-897-5988
- Fax
- 302-655-5049
Executives
- President, Chief Executive Officer, Director
- Sammy Farah
- Principal Financial and Accounting Officer
- Wendy Worcester
- Chief Operating Officer, Corporate Secretary
- Saryah Azmat
- Chief Scientific Officer
- Stewart Abbot
- Lead Independent Director
- Jerel Davis
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $10.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 23.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.23 |
Book Value | $0.67 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
